Carole Ho - Feb 11, 2022 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Chief Medical Officer
Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Feb 11, 2022
Transactions value $
-$101,284
Form type
4
Date filed
2/15/2022, 05:53 PM
Previous filing
Feb 11, 2022
Next filing
May 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale -$101K -2.92K -1.68% $34.71 171K Feb 11, 2022 See footnote F1, F2, F3, F4
holding DNLI Common Stock 25K Feb 11, 2022 See footnote F5
holding DNLI Common Stock 88.1K Feb 11, 2022 Direct F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $34.44 to $35.13 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7,469 restricted stock units held by the Reporting Person.
F4 The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
F5 The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust, for which the Reporting Person serves as trustee.
F6 Includes 87,687 restricted stock units.